about
Leishmania RNA virus: when the host pays the tollFailure of miltefosine treatment for visceral leishmaniasis in children and men in South-East AsiaManagement of trypanosomiasis and leishmaniasisThe anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasisLeishmaniasis, an emerging disease found in companion animals in the United StatesDissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methodsLeishmania trypanothione synthetase-amidase structure reveals a basis for regulation of conflicting synthetic and hydrolytic activitiesGlibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasisTrypanothione-dependent glyoxalase I in Trypanosoma cruziA Review of Impact of Bam Earthquake on Cutaneous Leishmaniasis and Status: Epidemic of Old Foci, Emergence of New Foci and Changes in Features of the DiseaseThe Dialogue of the Host-Parasite Relationship: Leishmania spp. and Trypanosoma cruzi InfectionNitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospectsComparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmaniaA Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment OutcomeA novel function for kojic acid, a secondary metabolite from Aspergillus fungi, as antileishmanial agentStudies of the Effectiveness of Bisphosphonate and Vanadium-Bisphosphonate Compounds In Vitro against Axenic Leishmania tarentolae.Structure of cyclophilin fromLeishmania donovaniat 1.97 Å resolutionN-Myristoyltransferase from Leishmania donovani: Structural and Functional Characterisation of a Potential Drug Target for Visceral LeishmaniasisStructures of a key interaction protein from the Trypanosoma brucei editosome in complex with single domain antibodiesHigh-resolution structures ofTrypanosoma bruceipteridine reductase ligand complexes inform on the placement of new molecular entities in the active site of a potential drug targetStructure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphateStructure of recombinantLeishmania donovanipteridine reductase reveals a disordered active siteExplorations of linked editosome domains leading to the discovery of motifs defining conserved pockets in editosome OB-foldsCrystal structure of a heterodimer of editosome interaction proteins in complex with two copies of a cross-reacting nanobodyThe narrow active-site cleft of O-acetylserine sulfhydrylase from Leishmania donovani allows complex formation with serine acetyltransferases with a range of C-terminal sequencesInhibitory Effect of Silver Nanoparticles on Trypanothione Reductase Activity and Leishmania infantum ProliferationCurrent challenges in treatment options for visceral leishmaniasis in India: a public health perspectiveAntileishmanial high-throughput drug screening reveals drug candidates with new scaffoldsKilling of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimonyGeographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trialAntimonial resistance in Leishmania donovani is associated with increased in vivo parasite burdenTherapeutic enhancement of protective immunity during experimental leishmaniasisIdentification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model systemTherapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c miceHigh throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinaseGene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensisMultiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencingIn vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasitesExperimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol
P2860
Q21131306-8A5B108A-30AD-47B0-8129-533098CB91EDQ21132005-EC8141AA-4168-47EB-9E64-3520F5B59772Q24596889-8519620D-5B25-403B-A0F6-0C6BF14F9DA6Q24633734-A98E40FA-B429-4C16-9C18-D6AC067A9DA6Q24647678-6A79477A-A1CE-4B7C-9213-2F41FB2E517FQ24649110-7F1C0BD8-8832-487D-BB22-705986EE9F25Q24655332-5151953C-B19D-4480-B8D5-B78F66F48E82Q24674183-29A3E9F0-F665-4534-B036-6D1C43CB6522Q24682276-FE845938-D858-4774-B619-67A7E221369CQ26745699-F4EC09B0-923A-4653-A5C0-A7C4890F26D2Q26829884-7AFFE062-B81C-4624-8CB9-E170DE6A0874Q26863285-9D80A9A4-3447-4768-9254-C3B5BE997B3CQ27009505-5A8FD4F4-6582-4684-BD8C-E300B87CE8DFQ27303693-43F9A813-1332-434A-9962-4F708585D6F4Q27316554-722F8C91-F212-4001-ADEA-F8D249380F21Q27349075-A49B57D5-9998-49D9-BC11-9D8ED1D0FA40Q27643739-91785F80-52E5-454C-90A5-0F9C8235D583Q27658775-6758F3A2-FBC0-4586-B46A-899E448C46B0Q27665314-60964451-30F4-4D4D-86B8-49305C41DB52Q27666140-3ACABCF5-DEC6-4C7B-AFB6-C3F065CC66C8Q27666287-33955435-4739-434E-BD7C-22B0AB79B6B4Q27666482-08979818-ED73-4D60-8523-75534860579DQ27671578-E2C55882-A650-4E58-9547-38A8DE43EA20Q27675299-6C72757E-45FF-4039-BD52-2A8F37371022Q27681897-DC00CFBE-AB79-4791-AA42-191E5EA55A9FQ27684102-39E5D5C6-3D76-4AF8-ABFC-43DD53CE5DCBQ28073426-39F094E7-A63A-4C71-ABD8-FF61EC69D5C7Q28473835-91F612CB-FEFC-44FF-9798-1176E6D7E1A3Q28474642-59A13142-8839-423A-AB2B-5E0117BA3E77Q28475794-206E28ED-FA65-4ABA-93DB-8A23C530F66CQ28475917-05702B08-5D05-48AF-8866-B1D137ED9C80Q28476400-B84EF0A4-F09C-4068-B80E-51CCA8EBFD5BQ28476803-3054B215-7FC6-46A3-894F-24C5E7C2DA6CQ28477163-E644D393-32F8-4F35-8B55-F39B13FD3CAEQ28477398-A0275A33-69AB-49DA-98CF-E2E1654E0A5FQ28477651-660A85C0-C736-432A-82CB-522131CFF853Q28478242-48C300CD-BFF3-413D-BA3F-CD7C907A5161Q28480626-645C5929-6A62-4366-9FFC-C6E03E785BE2Q28482212-00379BCE-C8E9-4631-B8C4-BAAD350DF413Q28483977-8D696AA9-50B0-4BC8-B03D-B1FC472FF870
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Drug resistance in leishmaniasis
@ast
Drug resistance in leishmaniasis
@en
type
label
Drug resistance in leishmaniasis
@ast
Drug resistance in leishmaniasis
@en
prefLabel
Drug resistance in leishmaniasis
@ast
Drug resistance in leishmaniasis
@en
P2860
P3181
P1476
Drug resistance in leishmaniasis
@en
P2093
P2860
P304
P3181
P356
10.1128/CMR.19.1.111-126.2006
P407
P577
2006-01-01T00:00:00Z